185 related articles for article (PubMed ID: 20407451)
1. Open-minded to open innovation and precompetitive collaboration.
Wagner JA
Clin Pharmacol Ther; 2010 May; 87(5):511-5. PubMed ID: 20407451
[No Abstract] [Full Text] [Related]
2. Arguments against precompetitive collaboration.
Vargas G; Boutouyrie B; Ostrowitzki S; Santarelli L
Clin Pharmacol Ther; 2010 May; 87(5):527-9. PubMed ID: 20407456
[No Abstract] [Full Text] [Related]
3. The Biomarkers Consortium: practice and pitfalls of open-source precompetitive collaboration.
Wagner JA; Prince M; Wright EC; Ennis MM; Kochan J; Nunez DJ; Schneider B; Wang MD; Chen Y; Ghosh S; Musser BJ; Vassileva MT
Clin Pharmacol Ther; 2010 May; 87(5):539-42. PubMed ID: 20407460
[TBL] [Abstract][Full Text] [Related]
4. How informatics can potentiate precompetitive open-source collaboration to jump-start drug discovery and development.
Perakslis ED; Van Dam J; Szalma S
Clin Pharmacol Ther; 2010 May; 87(5):614-6. PubMed ID: 20376001
[No Abstract] [Full Text] [Related]
5. The Critical Path Institute's approach to precompetitive sharing and advancing regulatory science.
Woosley RL; Myers RT; Goodsaid F
Clin Pharmacol Ther; 2010 May; 87(5):530-3. PubMed ID: 20407457
[TBL] [Abstract][Full Text] [Related]
6. Can open-source drug R&D repower pharmaceutical innovation?
Munos B
Clin Pharmacol Ther; 2010 May; 87(5):534-6. PubMed ID: 20407458
[TBL] [Abstract][Full Text] [Related]
7. Precompetitive research: a new prescription for drug development?
Woodcock J
Clin Pharmacol Ther; 2010 May; 87(5):521-3. PubMed ID: 20407454
[No Abstract] [Full Text] [Related]
8. The future is much closer collaboration between the pharmaceutical industry and academic medical centers.
Vallance P; Williams P; Dollery C
Clin Pharmacol Ther; 2010 May; 87(5):525-7. PubMed ID: 20407455
[No Abstract] [Full Text] [Related]
9. New IGF drug stirs competition in growth factor segment.
Ratner M
Nat Biotechnol; 2005 Oct; 23(10):1192. PubMed ID: 16211044
[No Abstract] [Full Text] [Related]
10. Precompetitive activity to address the biological data needs of drug discovery.
Sidders B; Brockel C; Gutteridge A; Harland L; Jansen PG; McEwen R; Michalovich D; Seidel H; Weiss B; Williams-Jones B; Woodwark M
Nat Rev Drug Discov; 2014 Feb; 13(2):83-4. PubMed ID: 24481293
[No Abstract] [Full Text] [Related]
11. Europe fiddles while innovation burns.
Frantz S
Nat Rev Drug Discov; 2005 Sep; 4(9):704-5. PubMed ID: 16178115
[No Abstract] [Full Text] [Related]
12. Market watch: Biopharma deal-making in 2014: a record year for M&A value.
Micklus A; Muntner S
Nat Rev Drug Discov; 2015 Feb; 14(2):84-5. PubMed ID: 25633786
[No Abstract] [Full Text] [Related]
13. Indian generics companies go on spending spree.
Jayaraman KS
Nat Rev Drug Discov; 2005 Aug; 4(8):616-7. PubMed ID: 16106583
[No Abstract] [Full Text] [Related]
14. Deal watch: recent trends in deal-making.
Dawkes A; Papp T
Nat Rev Drug Discov; 2010 Dec; 9(12):909. PubMed ID: 21119724
[No Abstract] [Full Text] [Related]
15. Small molecule challenges dominance of TNF-alpha inhibitors.
Sheridan C
Nat Biotechnol; 2008 Feb; 26(2):143-4. PubMed ID: 18259158
[No Abstract] [Full Text] [Related]
16. [From drug cost to drug price: steps and decisional processes].
Bruyninckx M; Nourissier C
Presse Med; 2012 May; 41 Suppl 1():S40-3. PubMed ID: 22487715
[No Abstract] [Full Text] [Related]
17. Open innovation: share or die..
Talaga P
Drug Discov Today; 2009 Nov; 14(21-22):1003-5. PubMed ID: 19778629
[No Abstract] [Full Text] [Related]
18. In vogue with venture.
Patou G
Nat Biotechnol; 2011 Nov; 29(11):967-9. PubMed ID: 22175076
[No Abstract] [Full Text] [Related]
19. Australian pharmaceutical policy: price control, equity, and drug innovation in Australia.
Doran E; Alexander Henry D
J Public Health Policy; 2008 Apr; 29(1):106-20. PubMed ID: 18368023
[TBL] [Abstract][Full Text] [Related]
20. In need of treatment? Merger control, pharmaceutical innovation, and consumer welfare.
Ben-Asher D; Juris M
J Leg Med; 2000 Sep; 21(3):271-349. PubMed ID: 11055154
[No Abstract] [Full Text] [Related]
[Next] [New Search]
